CagriSemaAmylin analogue plus GLP-1 receptor agonist
Phase 3 evidence; US submission announced; sponsor still calls it investigational
Novo Nordisk announced a US application in December 2025 and still called CagriSema investigational on 30 September 2026. An application is not FDA approval.Novo NordiskNovo Nordisk
EU marketing authorisation has not been verified in the reviewed sources. A trial, publication or pediatric-development plan is not an authorisation.
US approved product; Phase 3 clinical evidence; EU assessment latest verified record
FDA approved Foundayo (orforglipron) on 1 April 2026 for adult weight management with diet and physical activity, subject to product-specific indications and restrictions.FDA
The 14–17 September 2026 CHMP agenda lists orforglipron among applications with outstanding issues. A subsequent EU marketing authorisation has not been verified.EMA
Phase 3 clinical evidence; investigational in the cited paper
FDA approval has not been verified. Its August 2026 enforcement letter identifies a marketed survodutide product as unapproved; this product-specific enforcement record is not an exhaustive global regulatory search.FDA
EU marketing authorisation has not been verified in the reviewed sources. A trial, publication or pediatric-development plan is not an authorisation.
Approved product-specific uses; continuing clinical research
Wegovy has FDA-approved formulations for specified weight-management uses. The cited 2026 letter approves a new injection presentation and aligned labeling; this does not extend every indication to every semaglutide brand.FDA
EMA records EU authorisation of Wegovy for specified weight-management populations, with different restrictions for injections and tablets.EMA
Approved product-specific uses; continuing clinical research
Zepbound is FDA-approved for specified adult weight-management use and moderate-to-severe obstructive sleep apnea in adults with obesity; labels and population restrictions apply.FDAFDA
EMA records EU authorisation of Mounjaro for specified diabetes uses and adult weight management. US and EU product indications remain separate.EMA
A development stage does not establish approval. Not verified means the reviewed evidence did not establish that fact; it is not a comprehensive worldwide authorization search.
Zepbound is FDA-approved for specified adult weight-management uses and moderate-to-severe obstructive sleep apnea in adults with obesity. Product-label restrictions apply.
Evidence checked
2026-10-03
Read the profile ↗Conceptual SURVODUTIDE carton for this medicine profile, not a photograph of commercial packaging or clinical-trial supplies. The drug is investigational; this image does not establish regulatory approval.MEDICINE PROFILE
FDA approval has not been verified. An FDA warning letter dated 24 August 2026 identifies marketed survodutide products as unapproved. October Phase 3 publication is not approval evidence.
Wegovy: subcutaneous injection or oral tablet, depending on the approved formulation
FDA status
Wegovy formulations are FDA-approved for specified uses. Higher-dose Wegovy HD was approved on 19 March 2026. Approval is formulation- and indication-specific; this record does not extend every use to all semaglutide brands.
Evidence checked
2026-10-03
Read the profile ↗Conceptual RETATRUTIDE carton for this medicine profile, not a photograph of commercial packaging or clinical-trial supplies. The drug is investigational; this image does not establish regulatory approval.MEDICINE PROFILE
FDA states retatrutide is not a component of an FDA-approved drug; current sponsor sources call it investigational. Trial publication does not establish routine marketing approval.
Evidence checked
2026-10-03
Read the profile ↗Official Foundayo product photograph showing an orforglipron bottle in its US presentation. The pictured dose and packaging are not dosing advice. Image: Eli Lilly and Company. Official Foundayo media kit: https://www.lilly.com/news/media/foundayoMEDICINE PROFILE
FDA approved Foundayo on 1 April 2026 for specified adult weight-management use alongside a reduced-calorie diet and increased activity. Current label restrictions apply.
Evidence checked
2026-10-03
Read the profile ↗Conceptual CagriSema carton for this medicine profile, not a photograph of commercial packaging or clinical-trial supplies. The drug is investigational; this image does not establish regulatory approval.MEDICINE PROFILE
Amylin analogue cagrilintide combined with GLP-1 receptor agonist semaglutide
Administration
Subcutaneous injection in clinical trials
FDA status
Sponsor announced an FDA application on 18 December 2025 and still described CagriSema as investigational on 30 September 2026. Subsequent FDA approval has not been verified.